REVIAN Inc. has reported positive results for using the Revian Red System to treat patients with Central Centrifugal Cicatricial Alopecia (CCCA).1 Researchers from Wake Forest University School of Medicine in Salem-West, North Carolina, presented their findings regarding ACCC and the Revian Red System at the Society for Investigative Dermatology’s virtual 2021 annual meeting.
CCCA mainly affects black women and causes scarring hair loss. CCCA is thought to have environmental, genetic and inflammatory factors. Other forms of high level LED light or laser therapy are harsh on black women’s skin and can cause additional scarring or hyperpigmentation. 2 Adverse events from laser treatments can also change skin texture. Instead of laser treatments, low-intensity light therapy is more inclusive.
“To our knowledge, this is the first study evaluating the use of low-intensity light therapy for the management of ACCC and we were delighted to partner with the Revian team to evaluate a treatment for this devastating disease. said Amy McMichael MD, chair and professor. of Dermatology at Wake Forest University School of Medicine in Salem-West, North Carolina. “In my opinion, the Revian Red System shows promising results for a complex disease for which we have no treatment options.”
The Revian Red System uses a patented combination of two LED lights to stimulate the production and release of nitric oxide (NO), increase blood flow, reduce inflammation and inhibit the production of DHT which provides the best environment for growth hair. Black women with a biopsy-proven diagnosis of stage II-IV CCCA participated in the prospective clinical trial conducted by the Center for Dermatology Research, Department of Dermatology at Wake Forest University School of Medicine. 6 patients aged around 53.4 years participated in the study for 6 months. Participants experienced varying severities of disease for about 12 months before starting treatment.
The results indicated:
- Reduced loss of follicular openings and rupture in 75% of patients
- Post-treatment imaging showed short, repulsive vellus hairs and minimal inter- and perifollicular scaling
- Seventy-five percent of study participants had improved dermatological quality of life index (DLQI) after the end of the study
- Eighty percent of patients completed the study
- No adverse events reported
The positive results of the clinical study encourage more accurate diagnoses and treatments of ACCC in black women.
References:
- Clinical results indicate that Revian Red can serve as a treatment for central centrifugal cicatricial alopecia (CCCA) in African American women. Published June 2, 2022. Accessed June 8, 2022. https://www.prnewswire.com/news-releases/clinical-results-indicate-that-revian-red-may-serve-as-a-treatment-for- centrifugal-cicatricial-alopecia-ccca-in-african-american-women-301560228.html
- A Black Woman’s Guide to Laser and Light Therapy. Hello beauty. Published October 25, 2019. Accessed June 10, 2022. https://hellobeautiful.com/3062544/laser-and-light-therapy-for-african-american-skin/
